Other Stories

Full Video

Celltrion's inhaled COVID-19 treatment undergoes phase 1 clinical trial in Australia Updated: 2021-10-22 17:31:04 KST

A COVID-19 treatment developed by South Korean pharmaceutical giant Celltrion is currently undergoing a clinical trial.
Its U.S. partner, Inhalon Biopharma, started administering an inhaled-version of Regkirona to participants in Australia this month.
A total of 24 healthy individuals will receive the antibody therapeutic in the first phase of the clinical trial, followed by a phase 2 trial by the end of the year.
In August, Celltrion received approval from Australia's drug regulator to conduct efficacy evaluation studies for its inhaled treatment.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.